Monash-led biotechs Myostellar and GILZrx, have each received an additional AU$500,000 funding from Brandon BioCatalyst’s CUREator incubator, confirming the importance and value of spinning out university research into companies advancing new therapeutics that address significant health issues.
Myostellar is a discovery-stage biotechnology spin-out from Monash University developing novel therapeutics for skeletal muscle regeneration in patients with untreatable muscle disorders, with the lead indication in Duchenne Muscular Dystrophy (DMD). Led by Professor Peter Currie and Associate Professor Mikaël Martino at Monash’s Australian Regenerative Medicine Institute, Myostellar received CUREator funding in 2022 to translate their groundbreaking scientific findings from the lab towards the clinic.
“This top-up funding is incredibly important to advancing our therapeutic for stem-cell regeneration, bringing us closer to delivering a treatment for muscular dystrophy conditions,” said Professor Currie.
GILZrx received the top-up funding to advance the company’s development of novel drug alternatives to glucocorticoids in the treatment of inflammatory and autoimmune diseases, including lupus. GILZrx lead researchers Dr Sarah Jones and Professor Eric Morand from the Faculty of Medicine Nursing and Health Sciences, also received AU$500,000 initial funding from CUREator in 2022, which resulted in the formation of the Monash spinout.
Full story: CUREator funding confirms the importance and value of university research spin outs – Monash Innovation
